BR9913157A - Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto - Google Patents
Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, compostoInfo
- Publication number
- BR9913157A BR9913157A BR9913157-9A BR9913157A BR9913157A BR 9913157 A BR9913157 A BR 9913157A BR 9913157 A BR9913157 A BR 9913157A BR 9913157 A BR9913157 A BR 9913157A
- Authority
- BR
- Brazil
- Prior art keywords
- infection
- virus
- diseases associated
- infection caused
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
"PROCESSOS PARA TRATAR OU PREVENIR INFECçãO CAUSADA POR PELO MENOS UM VìRUS DAS FLAVIVIRIDAE E DOENçAS ASSOCIADAS COM A REFERIDA INFECçãO E INFECçãO CAUSADA POR PELO MENOS UM VìRUS DO GêNERO HEPACIVìRUS DAS FLAVIVIRIDAE E DOENçAS ASSOCIADAS COM A REFERIDA INFECçãO, COMPOSIçãO FARMACêUTICA PARA TRATAR OU PREVENIR INFECçõES VIRAIS, E, COMPOSTO". Proporciona-se compostos, composições e processos para o tratamento e a profilaxia de infecções e doenças associadas causadas por vírus da família Flaviviridae através da administração de determinados derivados de rodanina, e seus análogos, sendo que os ácidos alcanóicos de rodanina tri- e tetracíclica e ácidos benzóicos de rodanina são particularmente eficazes.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9747698P | 1998-08-21 | 1998-08-21 | |
US11321298P | 1998-12-22 | 1998-12-22 | |
US11932899P | 1999-02-09 | 1999-02-09 | |
US13558599P | 1999-05-24 | 1999-05-24 | |
US13558699P | 1999-05-24 | 1999-05-24 | |
PCT/US1999/018785 WO2000010573A1 (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9913157A true BR9913157A (pt) | 2001-05-15 |
Family
ID=27536838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9913157-9A BR9913157A (pt) | 1998-08-21 | 1999-08-19 | Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1128832A4 (pt) |
JP (1) | JP2002523371A (pt) |
KR (1) | KR20010099623A (pt) |
CN (1) | CN1325309A (pt) |
AU (1) | AU743411B2 (pt) |
BR (1) | BR9913157A (pt) |
CA (1) | CA2341970A1 (pt) |
ID (1) | ID27787A (pt) |
IL (1) | IL141456A0 (pt) |
WO (1) | WO2000010573A1 (pt) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003502320A (ja) * | 1999-06-10 | 2003-01-21 | ワーナー−ランバート・カンパニー | アミロイドタンパク質凝集を阻害し、アミロイド沈着物を画像化する方法に使用するためのローダニン誘導体 |
CN1384825A (zh) | 1999-08-31 | 2002-12-11 | 马克西亚药品公司 | 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用 |
WO2001077091A2 (en) * | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
IL154993A0 (en) * | 2000-09-29 | 2003-10-31 | Neurogen Corp | High affinity small molecule c5a receptor modulators |
IL157740A0 (en) | 2001-03-07 | 2004-03-28 | Incyte San Diego Inc | Heterocyclic derivatives and pharmaceutical compositions containing the same |
JP2004523571A (ja) | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Rxr活性化分子 |
GB2376944A (en) * | 2001-05-18 | 2002-12-31 | Pantherix Ltd | Polycyclic heterocyclic compounds and their therapeutic use |
WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
US20030134853A1 (en) | 2001-09-26 | 2003-07-17 | Priestley Eldon Scott | Compounds useful for treating hepatitis C virus |
EP1456187A4 (en) * | 2001-11-15 | 2005-02-09 | Incyte San Diego Inc | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
WO2003097621A1 (en) * | 2002-05-17 | 2003-11-27 | Qlt Inc. | Methods of using thiazolidinedithione derivatives |
US7041698B2 (en) | 2002-05-20 | 2006-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003248535A1 (en) | 2002-05-20 | 2003-12-12 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
DE60324552D1 (en) | 2002-05-20 | 2008-12-18 | Bristol Myers Squibb Co | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren |
BR0305426A (pt) | 2002-07-01 | 2004-08-24 | Upjohn Co | Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos |
WO2004002940A1 (en) | 2002-07-01 | 2004-01-08 | Pharmacia & Upjohn Company | Inhibitors of hcv ns5b polymerase |
FR2845000B1 (fr) * | 2002-09-27 | 2005-05-27 | Oreal | Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute |
US7235573B2 (en) | 2002-09-30 | 2007-06-26 | The Regents Of The University Of California | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors |
KR20050061501A (ko) * | 2002-09-30 | 2005-06-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 낭종 섬유증 트랜스막 전도도 조절기 단백질 억제제 및이의 용도 |
WO2004043955A1 (en) * | 2002-11-13 | 2004-05-27 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
EP1629000B1 (en) | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
WO2005007141A2 (en) | 2003-07-11 | 2005-01-27 | Proteologics, Inc. | Ubiquitin ligase inhibitors and methods related thereto |
FR2858324A1 (fr) * | 2003-07-30 | 2005-02-04 | Centre Nat Rech Scient | Nouveaux composes antibiotiques, compositions pharmaceutiques les contenant et leurs utilisations |
US7112601B2 (en) | 2003-09-11 | 2006-09-26 | Bristol-Myers Squibb Company | Cycloalkyl heterocycles for treating hepatitis C virus |
WO2005041951A2 (en) * | 2003-10-28 | 2005-05-12 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives for use as antiviral agents |
US7026339B2 (en) | 2003-11-07 | 2006-04-11 | Fan Yang | Inhibitors of HCV NS5B polymerase |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102911161A (zh) | 2004-02-20 | 2013-02-06 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
PT1719773E (pt) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
WO2006117306A1 (en) | 2005-05-04 | 2006-11-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
JP2008543836A (ja) * | 2005-06-15 | 2008-12-04 | ニューヨーク ブラッド センター | 複素環置換フェニルフランおよび関連化合物を含む抗ウイルス組成物 |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
EP2019830A4 (en) * | 2006-05-04 | 2011-01-19 | Inst Hepatitis & Virus Res | INHIBITORS OF THE SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR THE TREATMENT OF A CHRONIC HEPATITIS VIRUS |
EP2084175B1 (en) | 2006-10-10 | 2010-12-29 | Medivir AB | Hcv nucleoside inhibitor |
WO2008082537A2 (en) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Compounds for modulating integrin cd11b/cd18 |
MX2009013830A (es) | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
EA019749B1 (ru) | 2007-06-29 | 2014-06-30 | Джилид Сайэнс, Инк. | Противовирусные соединения |
JP2011502998A (ja) | 2007-11-01 | 2011-01-27 | ザ ユーエイビー リサーチ ファウンデイション | ウイルス感染の治療および予防 |
EP2543368A1 (en) | 2007-12-11 | 2013-01-09 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
US7947717B2 (en) | 2008-07-18 | 2011-05-24 | Burnham Institute For Medical Research | Inhibitors of lethal factor protease |
BRPI0922366B8 (pt) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
MX2011005896A (es) | 2008-12-03 | 2011-09-29 | Presidio Pharmaceuticals Inc | Inhibidores de hcv ns5a. |
EA201190224A1 (ru) | 2009-03-27 | 2012-03-30 | Пресидио Фармасьютикалс, Инк. | Ингибиторы гепатита c, содержащие конденсированные кольца |
BR112012011221A2 (pt) | 2009-11-14 | 2016-04-05 | Hoffmann La Roche | biomarcadores para prever resposta rápida ao tratamento de hcv |
CN102656459A (zh) | 2009-12-02 | 2012-09-05 | 弗·哈夫曼-拉罗切有限公司 | 用于预测对hcv治疗持续应答的生物标志物 |
EP2515903A4 (en) * | 2009-12-23 | 2013-07-10 | Peter Maccallum Cancer Inst | COMPOUNDS, PREPARATION AND USES THEREOF |
WO2011149856A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
KR101159000B1 (ko) * | 2010-06-18 | 2012-06-21 | (주) 에빅스젠 | 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 |
US9023876B2 (en) | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
US9255088B2 (en) | 2010-08-11 | 2016-02-09 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2012175581A1 (en) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Antiviral compounds |
MX2014003705A (es) | 2011-10-10 | 2014-07-22 | Hoffmann La Roche | Compuestos antivirales. |
KR20140104030A (ko) | 2011-12-16 | 2014-08-27 | 에프. 호프만-라 로슈 아게 | Hcv ns5a의 억제제 |
DK2794628T3 (en) | 2011-12-20 | 2017-07-10 | Riboscience Llc | 4'-AZIDO-3'-FLUORO-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION |
UA111761C2 (uk) | 2011-12-20 | 2016-06-10 | Рібосаєнс Ллс | 2',4'-дифтор-2'-метилзаміщені нуклеозидні похідні як інгібітори реплікації phk вірусу гепатиту c |
US9090559B2 (en) | 2012-02-24 | 2015-07-28 | Hoffmann-La Roche Inc. | Antiviral compounds |
WO2013142346A1 (en) | 2012-03-23 | 2013-09-26 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
EP2838614B1 (en) | 2012-04-20 | 2019-09-11 | GB006, Inc. | Compositions for regulating integrins |
US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
EP2948440B1 (en) | 2013-01-23 | 2017-04-12 | F. Hoffmann-La Roche AG | Antiviral triazole derivatives |
KR20150114566A (ko) | 2013-03-05 | 2015-10-12 | 에프. 호프만-라 로슈 아게 | 항바이러스 화합물 |
RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
NZ714927A (en) | 2013-05-16 | 2020-09-25 | Riboscience Llc | 4’-fluoro-2’-methyl substituted nucleoside derivatives |
EA201592185A1 (ru) | 2013-05-16 | 2016-05-31 | Рибосайенс Ллк | 4'-азидо, 3'-дезокси-3'-фторзамещенные нуклеозидные производные |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
AR112702A1 (es) | 2017-09-21 | 2019-11-27 | Riboscience Llc | Derivados de nucleósidos sustituidos con 4-fluoro-2-metilo como inhibidores de la replicación de hcv arn |
KR101893988B1 (ko) | 2018-05-16 | 2018-08-31 | (주)에빅스젠 | 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물 |
TW202348228A (zh) | 2022-02-24 | 2023-12-16 | 德商艾斯巴赫生物有限公司 | 病毒組合療法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909467A (en) * | 1958-07-09 | 1959-10-20 | Us Vitamin Pharm Corp | 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione |
US3888984A (en) * | 1972-03-13 | 1975-06-10 | Lilly Industries Ltd | Oxazole and imidazole derivatives as antifungal agents |
AU6610081A (en) * | 1980-01-24 | 1981-07-30 | Senju Pharmaceutical Co., Ltd. | Thiazolidine derivatives |
US4367234A (en) * | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
MX9302578A (es) * | 1992-05-01 | 1994-08-31 | Commw Scient Ind Res Org | Agentes antivirales. |
CA2153553A1 (en) * | 1994-07-13 | 1996-01-14 | Hidekazu Suzuki | Stable lipid emulsion |
US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
DE19645974C1 (de) * | 1996-11-07 | 1998-08-13 | Andreas Johannes Kesel | (Z)-5-[[3-Hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methylen]-2-thioxo-4- thiazolidinon, Verfahren zu dessen Herstellung und Verwendung |
-
1999
- 1999-08-19 IL IL14145699A patent/IL141456A0/xx unknown
- 1999-08-19 JP JP2000565894A patent/JP2002523371A/ja active Pending
- 1999-08-19 CA CA002341970A patent/CA2341970A1/en not_active Abandoned
- 1999-08-19 CN CN99812282A patent/CN1325309A/zh active Pending
- 1999-08-19 BR BR9913157-9A patent/BR9913157A/pt not_active Application Discontinuation
- 1999-08-19 EP EP99942288A patent/EP1128832A4/en not_active Withdrawn
- 1999-08-19 ID IDW20010428A patent/ID27787A/id unknown
- 1999-08-19 AU AU55702/99A patent/AU743411B2/en not_active Ceased
- 1999-08-19 WO PCT/US1999/018785 patent/WO2000010573A1/en not_active Application Discontinuation
- 1999-08-19 KR KR1020017002117A patent/KR20010099623A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU743411B2 (en) | 2002-01-24 |
JP2002523371A (ja) | 2002-07-30 |
IL141456A0 (en) | 2002-03-10 |
WO2000010573A1 (en) | 2000-03-02 |
ID27787A (id) | 2001-04-26 |
EP1128832A1 (en) | 2001-09-05 |
CN1325309A (zh) | 2001-12-05 |
EP1128832A4 (en) | 2003-03-05 |
CA2341970A1 (en) | 2000-03-02 |
KR20010099623A (ko) | 2001-11-09 |
AU5570299A (en) | 2000-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9913157A (pt) | Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto | |
BR0312286A (pt) | pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae | |
BRPI0306993B8 (pt) | polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível | |
BR9810745A (pt) | Derivados de benzimidazol | |
BR9913935A (pt) | Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo | |
BRPI0414045A (pt) | administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c | |
BR0013771A (pt) | Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica | |
MY117892A (en) | Therapeutic compounds | |
BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
BR0008840A (pt) | Derivados de camptotecina tendo atividade antitumoral | |
UY28084A1 (es) | Derivados antivirales de nucleosidos | |
BR0113755A (pt) | Composto multimérico, processo para a preparação de composto, composição farmacêutica que compreende o composto, processo para o tratamento e/ou profilaxia e detecção de uma infecção por virus, utilização do composto, e inalador que contém a composição | |
BR9913406A (pt) | Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
BRPI0508079A (pt) | composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c | |
EP0270317A3 (en) | Pharmaceutical compositions for the treatment of diseases caused by viruses | |
ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
KR890003402A (ko) | 전신 dsRNA 치료에 의해 숙주방어 조절자를 생물학적 액체내에서 릴리즈시키는 방법 | |
KR890003387A (ko) | 국소활성을 갖는 이중-가닥 RMAs조성물 | |
BR0110382A (pt) | Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos | |
ES2123499T3 (es) | Metodos y composiciones para tratamiento de infecciones virales. | |
BR9810710A (pt) | Composição farmacêutica para a prevenção ou tratamento de prurido, e, processo para prevenir ou tratar prurido em um mamìfero | |
AP9801286A0 (en) | Therapeutic compounds. | |
AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
BR0111933A (pt) | Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |